Utomilumab - Pfizer

Drug Profile

Utomilumab - Pfizer

Alternative Names: PF-05082566; PF-2566; PF-5082566

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Immatics US; Kyowa Hakko Kirin; M. D. Anderson Cancer Center; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Oropharyngeal cancer; Solid tumours
  • Phase I Colorectal cancer; Ovarian cancer
  • No development reported B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Jul 2018 Phase-I clinical trials in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03318900)
  • 21 Jun 2018 Phase-II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03414658)
  • 24 Apr 2018 Pfizer and Kyowa Hakko Kirin terminate phase I trial in Solid tumours in USA (NCT02444793)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top